Chimeric mice with hepatocyte-humanized liver as an appropriate model to study human peroxisome proliferator-activated receptor-α

Toxicologic Pathology

Volumn 43, Issue 2, 2015, Pages 233-248

  Tateno, Chise ^a,b,c   Yamamoto, Toshinobu ^d   Utoh, Rie ^a,e   Yamasaki, Chihiro ^a,c   Ishida, Yuji ^b,c   Myoken, Yuka ^c   Oofusa, Ken ^c,f   Okada, Miyoko ^d   Tsutsui, Naohisa ^d   Yoshizato, Katsutoshi ^a,b,c  

^a Hiroshima Prefectural Institute of Industrial Science and Technology   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c PhoenixBio USA Corporation   (Japan)

^d MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f IDEA CONSULTANTS INC   (Japan)

Author keywords

fenofibrate; human hepatocytes; humanized mice; PPAR

Indexed keywords

FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; ANTILIPEMIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; DEOXYGENATION; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER CELL; LIVER HYPERTROPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SEVERE COMBINED IMMUNODEFICIENCY; TRANSGENIC MOUSE; ANIMAL; CELL TRANSPLANTATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; LIVER; METABOLISM; PEROXISOME; SCID MOUSE; SIGNAL TRANSDUCTION;

MUS; MUS MUSCULUS; RODENTIA;

ANIMALS; CELL TRANSPLANTATION; FEMALE; FENOFIBRATE; GENE EXPRESSION; HEPATOCYTES; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER; MALE; MICE; MICE, SCID; PEROXISOMES; PPAR ALPHA; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 84924700044     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623314544378     Document Type: Article

References (45)

1. Ammerschlaeger M., Beigel J., Klein K.-U., Mueller S. O.. Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes. Toxicol Sci. 2004 ; 78: 229-40
2. Bentley P., Calder I., Elcombe C., Grasso P., Stringer D., Wiegand H. J.. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol. 1993 ; 31: 857-907
3. Blümcke S., Schwartzkopff W., Lobeck H., Edmondson N. A., Prentice D. E., Blane G. F.. Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis. 1983 ; 46: 105-16
4. Cattley R. C., DeLuca J., Elcombe C., Fenner-Crisp P., Lake B. G., Marsman D. S., Pastoor T. A., Popp J. A., Robinson D. E., Schwetz B., Tugwood J., Wahli W.. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?. Regul Toxicol Pharmacol. 1998 ; 27: 47-60
5. Chang E. Y., Son S. K., Ko H. S., Baek S. H., Kim J. H., Kim J. R.. Induction of apoptosis by the overexpression of an alternative splicing variant of mitochondrial thioredoxin reductase. Free Radic Biol Med. 2005 ; 39: 1666-75
6. Cheung C., Akiyama T. E., Ward J. M., Nicol C. J., Feigenbaum L., Vinson C., Gonzalez F. J.. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res. 2004 ; 64: 3849-54
7. Fidaleo M.. Human health risk assessment for peroxisome proliferators: More than 30 years of research. Exp Toxicol Pathol. 2009 ; 61: 215-21
8. Foster J. R., Jacobsen M., Kenna G., Schulz-Utermoehl T., Morikawa Y., Salmu J., Wilson I. D.. Differential effect of Troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB Hepatic Chimeric mouse. Toxicol Pathol. 2012 ; 40: 1106-16
9. Gariot P., Barrat E., Mejean L., Pointel J. P., Drouin P.. Fenofibrate and human liver. Lack of proliferation of peroxisomes. Arch Toxicol. 1983 ; 53: 151-63
10. Gonzalez F. J., Shah Y. M.. PPARalpha: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology. 2008 ; 246: 2-8
11. Guyton K. Z., Chiu W. A., Bateson T. F., Jinot J., Scott C. S., Brown R. C., Caldwell J. C.. A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants. Environ Health Perspect. 2009 ; 117: 1664-72
12. Hsu M. H., Savas U., Griffin K. J., Johnson E. F.. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J Biol Chem. 2001 ; 276: 27950-8
13. Kakuni M., Morita M., Matsuo K., Katoh Y., Nakajima M., Tateno C., Yokoi T.. Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. Toxicol Lett. 2012 ; 214: 9-18
14. Katoh M., Matsui T., Nakajima M., Tateno C., Kataoka M., Soeno Y., Horie T., Iwasaki K., Yoshizato K., Yokoi T.. Expression of human cytochrome P450 in chimeric mice with humanized liver. Drug Metab Dispos. 2004 ; 32: 1402-10
15. Katoh M., Matsui T., Okumura H., Nakajima M., Nishimura M., Naito S., Tateno C., Yoshizato K., Yokoi T.. Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos. 2005 ; 33: 1333-40
16. Kristensen D. B., Imamura K., Miyamoto Y., Yoshizato K.. Mass spectrometric approaches for the characterization of proteins on a hybrid quadrupole time-of-flight (Q-TOF) mass spectrometer. Electrophoresis. 2000 ; 21: 430-9
17. Kroetz D. L., Yook P., Costet P., Bianchi P., Pineau T.. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem. 1998 ; 273: 31581-9
18. Lawrence J. W., Li Y., Chen S., DeLuca J. G., Berger J. P., Umbenhauer D. R., Moller D. E., Zhou G.. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson. J Biol Chem. 2001 ; 276: 31521-7
19. Mates J. M.. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology. 2000 ; 153: 83-104
20. Maxwell A. G., Yu-Jui Y. W.. Mechanisms of Resistance of hepatocyte retinoid X receptor a-null mice to WY - 14,643-induced hepatocyte proliferation and cholestasis. J Biol Chem. 2009 ; 284: 9321-30
21. Mercer D. E., Schiller D. E., Elliott J. F., Douglas D. N., Hao C., Rinfret A., Addison W. R., Fischer K. P., Churchill T. A., Lakey J. R., Tyrrell D. L., Kneteman N. M.. Hepatitis C virus replication in mice with chimeric human livers. Nat Med. 2001 ; 7: 927-33
22. Morimura K., Cheung C., Ward J. M., Reddy J. K., Gonzalez F. J.. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor α to Wy-14,643-induced liver tumorigenesis. Carcinogenesis. 2006 ; 27: 1074-80
23. Nishimura J., Dewa Y., Muguruma M., Kuroiwa Y., Yasuno H., Shima T., Jin M., Takahashi M., Umemura T., Mitsumori K.. Effect of fenofibrate on oxidative DNA damage and on gene expression related to cell proliferation and apoptosis in rats. Toxicol Sci. 2007 ; 97: 44-54
24. Nishimura M., Yoshitsugu H., Yokoi T., Tateno C., Kataoka M., Horie T., Yoshizato K., Naito S.. Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica. 2005 ; 35: 877-90
25. Novikoff A. B., Goldfischer S.. Visualization of peroxisomes (microbodies) and mitochondria with diaminobenzidine. J Histochem Cytochem. 1969 ; 17: 675-80
26. Palmer C. N., Hsu M. H., Griffin K. J., Raucy J. L., Johnson E. F.. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol. 1998 ; 53: 14-22
27. Parzefall W., Berger W., Kainzbauer E., Teufelhofer O., Schulte-Hermann R., Thurman R. G.. Peroxisome proliferators do not increase DNA synthesis in purified rat hepatocytes. Carcinogenesis. 2001 ; 22: 519-23
28. Peters J. M., Aoyama T., Cattley R. C., Nobumitsu U., Hashimoto T., Gonzalez F. J.. Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver. Carcinogenesis. 1998 ; 19: 1989-94
29. Peters J. M., Cheung C., Gonzalez F. J.. Peroxisome proliferator-activated receptor-alpha and liver cancer: Where do we stand?. J Mol Med. 2005 ; 83: 774-85
30. Pyper S. R., Viswakarma N., Yu S., Reddy J. K.. PPARalpha: Energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2012 ; 8: e002
31. Rakhshandehroo M., Sanderson L. M., Matilainen M., Stienstra R., Carlberg C., de Groot P. J., Müller M., Kersten S.. Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Res. 2007 ; 2007: 26839
32. Rininger J. A., Goldsworthy T. L., Babish J. G.. Time course comparison of cell-cycle protein expression following partial hepatectomy and WY14,643-induced hepatic cell proliferation in F344 rats. Carcinogenesis. 1997 ; 18: 935-41
33. Sandgren E. P., Palmiter R. D., Heckel J. L., Daugherty C. C., Brinster R. L., Degen J. L.. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell. 1991 ; 66: 245-56
34. Shoda J., Okada K., Inada Y., Kusama H., Utsunomiya H., Oda K., Yokoi T., Yoshizato K., Suzuki H.. Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol Res. 2007 ; 37: 548-56
35. Tachibana K., Yamasaki D., Ishimoto K., Doi T.. The role of PPARs in cancer. PPAR Res. 2008 2008 ;: 102737
36. Tateno C., Miya F., Wake K., Kataoka M., Ishida Y., Yamasaki C., Yanagi A., Kakuni M., Wisse E., Verheyen F., Inoue K., Sato K., Kudo A., Arii S., Itamoto T., Asahara T., Tsunoda T., Yoshizato K.. Morphological and microarray analyses of human hepatocytes from xenogeneic host livers. Lab Invest. 2013 ; 93: 54-71
37. Tateno C., Yoshizane Y., Saito N., Kataoka M., Utoh R., Yamasaki C., Tachibana A., Soeno Y., Asahina K., Hino H., Asahara T., Yokoi T., Furukawa T., Yoshizato K.. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol. 2004 ; 165: 901-12
38. Tsuge M., Hiraga N., Takaishi H., Noguchi C., Oga H., Imamura M., Takahashi S., Iwao E., Fujimoto Y., Ochi H., Chayama K., Tateno C., Yoshizato K.. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology. 2005 ; 42: 1046-54
39. Umehara T., Sudoh M., Yasui F., Matsuda C., Hayashi Y., Chayama K., Kohara M.. Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem Biophys Res Commun. 2006 ; 346: 67-73
40. Walgren J. E., Kurtz D. T., McMillan J. M.. Expression of PPAR (alpha) in human hepatocytes and activation by trichloroacetate and dichloroacetate. Res Commun Mol Pathol Pharmacol. 2000 ; 108: 116-32
41. Yamagata A., Kristensen D. B., Takeda Y., Miyamoto Y., Okada K., Inamatsu M., Yoshizato K.. Mapping of phosphorylated proteins on two-dimensional polyacrylamide gels using protein phosphatase. Proteomics. 2002 ; 2: 1267-76
42. Yang Q., Nagano T., Shah Y., Cheung C., Ito S., Gonzalez F. J.. The PPAR alpha-humanized mouse: A model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci. 2008 ; 101: 132-9
43. Yoshizato K., Tateno C.. A human hepatocyte-bearing mouse: An animal model to predict drug metabolism and effectiveness in humans. PPAR Res. 2009 2009 ;: 476217
44. Yoshizato K., Tateno C.. A mouse with humanized liver as an animal model for predicting drug effects and for studying hepatic viral infection: Where to next?. Expert Opin Drug Metab Toxicol. 2013 ; 9: 1419-35
45. Yu S., Rao S., Reddy J. K.. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med. 2003 ; 3: 561-72